Elastofibroma Dorsi: Clinical Features, Surgical Outcomes, and Risk Factors

September 7, 2025 updated by: Caner İşevi, MD, Ondokuz Mayıs University

Clinical Characteristics of Elastofibroma Dorsi, Long-Term Outcomes After Surgical Resection, and Analysis of Risk Factors

This study aims to retrospectively evaluate patients who underwent surgical treatment for elastofibroma dorsi, a rare benign tumor typically located in the subscapular region of the chest wall. The study will analyze demographic and clinical features, risk factors, diagnostic imaging methods, postoperative complications, and recurrence rates. By identifying potential predictors of complications and recurrence, the study hopes to contribute to the understanding and management of this silent and often incidental lesion.

Study Overview

Status

Active, not recruiting

Conditions

Intervention / Treatment

Study Type

Observational

Enrollment (Estimated)

130

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

The study population consists of adult patients (aged 18 and older) who were diagnosed with elastofibroma dorsi and underwent surgical resection at a single tertiary care center between 2010 and 2025. All included patients had histopathologically confirmed diagnoses and at least one month of postoperative follow-up available in hospital records.

Description

Inclusion Criteria:

  • Patients who underwent surgical treatment for elastofibroma dorsi
  • Histopathological confirmation of the diagnosis
  • Minimum of 1-month postoperative follow-up available
  • Age 18 years or older
  • Accessible medical and imaging records in hospital archives
  • Signed informed consent available in patient records (if applicable)

Exclusion Criteria:

  • Patients diagnosed with elastofibroma dorsi but not treated surgically
  • Cases without histopathological confirmation
  • Incomplete or insufficient medical and radiological records
  • Postoperative follow-up period less than 1 month
  • Patients younger than 18 years
  • Absence of documented informed consent (if applicable)

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Surgically Treated Elastofibroma Dorsi Patients
This cohort includes patients diagnosed with elastofibroma dorsi who underwent surgical resection between 2010 and 2025. Patients were retrospectively evaluated for demographic characteristics, clinical features, diagnostic methods, surgical findings, postoperative complications, and recurrence during follow-up.
Other: Retrospective Medical Record Review
Review of archived medical, surgical, and radiological records of patients diagnosed with elastofibroma dorsi and treated surgically. No active intervention was administered as part of the study.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Completion of Retrospective Data Collection Form
Time Frame: Within 3 months after data collection begins
Completion of data collection from medical records of patients diagnosed with elastofibroma dorsi who underwent surgical treatment, including demographic features, clinical presentation, imaging modalities, surgical outcomes, postoperative complications, and recurrence.
Within 3 months after data collection begins

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Ondokuz Mayıs University

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

January 1, 2010

Primary Completion (Estimated)

September 30, 2025

Study Completion (Estimated)

December 1, 2025

Study Registration Dates

First Submitted

May 30, 2025

First Submitted That Met QC Criteria

June 6, 2025

First Posted (Actual)

June 8, 2025

Study Record Updates

Last Update Posted (Estimated)

September 12, 2025

Last Update Submitted That Met QC Criteria

September 7, 2025

Last Verified

May 1, 2025

More Information

Terms related to this study

Keywords

Other Study ID Numbers

  • B.30.2.ODM.0.20.08/280

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Elastofibroma Dorsi

Clinical Trials on Retrospective Medical Record Review

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Lebanon

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe